US/UK/Canada

Share

Pick a time period -
Tags ( Active)

Circio announces circVec LNP-delivery collaboration with Certest progressing to in vivo testing

· Certest Biotec, S.L. and Circio are collaborating to create and test circVec DNA-LNP formulations for potential therapeutic applications · Certest´s proprietary ionizable lipids and their optimized LNP formulations have shown impressive delivery specificity to several tissues of interest to Circio, including lung, liver and spleen · Technical formulation and in vitro analysis of circVec-LNP formulations by Certest have been successful, and the collaboration will now progress to in vivo delivery testingOslo, Norway 19 November 2024 – Circio Holding ASA (OSE: CRNA), a biotechnology

Circio Holding ASA: Registration of share capital increase following conversion of convertible bonds

Oslo, 14 November 2024: Reference is made to the stock exchange announcement by Circio Holding ASA (OSE:CRNA) (“CIRCIO” or the “Company“) on 12 November 2024, regarding the requested conversion of convertible bonds by Atlas Special Opportunities, LLC. The share capital increase has now been registered with the Norwegian Register of Business Enterprises (Nw. Foretaksregisteret). The Company’s new share capital is NOK 25,184,037.00 divided into 41,973,395 shares, each with a nominal value of NOK 0.60.

Circio Holding ASA: Requested Conversion of Convertible Bonds

Reference is made to Circio Holding ASA's (the "Company") outstanding convertible bonds as issued to Atlas Special Opportunities, LLC ("Atlas") under the Investment Agreement entered into between Atlas and the Company in March 2023. Atlas has, by a notice of conversion, requested conversion of convertible bonds with a nominal value of NOK 5,000,000 which, pursuant to the bond terms, are convertible into 8,287,750 new shares in the Company at a conversion price of NOK 0.6033. The Company's share capital will accordingly be increased by NOK 4,972,650.00 by the issuance of 8,287,750 new

Circio Holding ASA: Registration of share capital increase following conversion of convertible bonds

Oslo, 5 November 2024: Reference is made to the stock exchange announcement by Circio Holding ASA (OSE:CRNA) (“CIRCIO” or the “Company“) on 1 November 2024, regarding the requested conversion of convertible bonds by Atlas Special Opportunities, LLC. The share capital increase has now been registered with the Norwegian Register of Business Enterprises (Nw. Foretaksregisteret). The Company’s new share capital is NOK 20,211,387.00 divided into 33,685,645 shares, each with a nominal value of NOK 0.60.

Circio Holding ASA – Conversion of Convertible Bonds and funding requested under financing commitment from Atlas

Reference is made to Circio Holding ASA's (the "Company") outstanding convertible bonds as issued to Atlas Special Opportunities, LLC ("Atlas") under the Investment Agreement (the “Agreement”) entered into between Atlas and the Company in March 2023, and later amended in September 2023 and June 2024. Atlas has, by a notice of conversion, requested conversion of convertible bonds with a nominal value of NOK 2,500,000 which, pursuant to the bond terms, are convertible into 4,165,972 new shares in the Company at a conversion price of NOK 0.60. The Company's share capital will accordingly

Circio Holding ASA: Registration of share capital increase following conversion of convertible bonds

Oslo, 31 October 2024: Reference is made to the stock exchange announcement by Circio Holding ASA (OSE:CRNA) (“CIRCIO” or the “Company“) on 25 October 2024, regarding the requested conversion of convertible bonds by Atlas Special Opportunities, LLC. The share capital increase has now been registered with the Norwegian Register of Business Enterprises (Nw. Foretaksregisteret). The Company’s new share capital is NOK 17,711,803.80 divided into 29,519,673 shares, each with a nominal value of NOK 0.60.

Circio Holding ASA: Requested Conversion of Convertible Bonds

Reference is made to Circio Holding ASA's (the "Company") outstanding convertible bonds as issued to Atlas Special Opportunities, LLC ("Atlas") under the Investment Agreement entered into between Atlas and the Company in March 2023. Atlas has, by a notice of conversion, requested conversion of convertible bonds with a nominal value of NOK 2,500,000 which, pursuant to the bond terms, are convertible into 4,166,666 new shares in the Company at a conversion price of NOK 0.6. The Company's share capital will accordingly be increased by NOK 2,499,999.60 by the issuance of 4,166,666 new

Circio Holding ASA: Registration of share capital increase following conversion of convertible bonds

Oslo, 25 October 2024: Reference is made to the stock exchange announcement by Circio Holding ASA (OSE:CRNA) (“CIRCIO” or the “Company“) on 23 October 2024, regarding the requested conversion of convertible bonds by Atlas Special Opportunities, LLC. The share capital increase has now been registered with the Norwegian Register of Business Enterprises (Nw. Foretaksregisteret). The Company’s new share capital is NOK 15,211,804.20 divided into 25,353,007 shares, each with a nominal value of NOK 0.60.

Circio presents circVec circular RNA in vivo expression proof-of-concept data at ESGCT 2024 annual meeting

· Circio selected to present its circVec circular RNA expression platform at the European Society of Cell and Gene Therapy (ESGCT) annual meeting in Rome 22-25 October; a prestigious and widely attended international gene therapy conference · Circio presented new circVec protein expression data showing statistically significant advantage vs. conventional mRNA-based vector expression both in vitro and in vivo · The circVec 2.1 generation shows 15x increase in protein expression in vivo, and has the potential to substantially improve on the performance of current gold-standard gene

Circio Holding ASA: Requested Conversion of Convertible Bonds

Reference is made to Circio Holding ASA's (the "Company") outstanding convertible bonds as issued to Atlas Special Opportunities, LLC ("Atlas") under the Investment Agreement entered into between Atlas and the Company in March 2023. Atlas has, by a notice of conversion, requested conversion of convertible bonds with a nominal value of NOK 500,000 which, pursuant to the bond terms, are convertible into 833,333 new shares in the Company at a conversion price of NOK 0.6. The Company's share capital will accordingly be increased by NOK 499,999.80 by the issuance of 833,333 new shares upon

Circio selected for oral presentation at ESGCT 2024 annual meeting

· Circio has been selected to present its circVec circular RNA expression platform at the European Society of Cell and Gene Therapy (ESGCT) annual meeting 2024, taking place on 22-25 October 2024 in Rome, Italy · ESGCT is one of the most prestigious and widely attended international conferences in the gene therapy field · In the presentation, Circio wil showcase the latest developments and in vivo data for its circVec circular RNA expression platform designed to enhance gene therapyOslo, Norway 24 September 2024 – Circio Holding ASA (OSE: CRNA), a biotechnology company developing next

Circio Holding ASA: Invitation to first half-year 2024 presentation on Thursday 29 August at 10:00am CEST

Oslo, Norway, 26 August 2024 – Circio Holding ASA (OSE: CRNA) will announce its first half-year 2024 results on Thursday 29 August 2024. Circio’s management will present the results in a live-streamed webcast at 10:00 am CEST to investors, analysts and the press.The half-year report and the presentation will be made available online at www.circio.com in the Investors section from 07:00 am CEST on 29 August 2024. Presentation There will be a virtual presentation of the results in a live webcast on Thursday 29 August at 10.00am CEST, click here for access 

Circio Holding ASA – Mandatory notification of trade by primary insiders and close associates related to the rights issue

NOT FOR DISTRIBUTION OR RELEASE, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, THE UNITED KINGDOM, AUSTRALIA, CANADA, HONG KONG OR JAPAN, OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN.Oslo, 9 July 2024: Reference is made to the stock exchange announcement published by Circio Holding ASA (the "Company") earlier today, 9 July 2024, regarding the final results of the rights issue (the "Rights Issue"). The following primary

Circio Holding ASA – Final results of the rights issue

NOT FOR DISTRIBUTION OR RELEASE, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, THE UNITED KINGDOM, AUSTRALIA, CANADA, HONG KONG OR JAPAN, OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN.Oslo, 9 July 2024: Reference is made to the stock exchange announcement published by Circio Holding ASA (the "Company") on 8 July 2024 regarding the preliminary results of the rights issue of between 3,658,000 new shares to 20,732,010 new shares in

Circio Holding ASA – Preliminary results of the rights issue

NOT FOR DISTRIBUTION OR RELEASE, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, THE UNITED KINGDOM, AUSTRALIA, CANADA, HONG KONG OR JAPAN, OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN.Oslo, 8 July 2024: Reference is made to the stock exchange announcement published by Circio Holding ASA (the "Company") on 19 June 2024 regarding the general meeting's approval of a rights issue of between 3,658,000 new shares to 20,732,010 new

Circio Holding ASA – Last day of the subscription period in the rights issue

NOT FOR DISTRIBUTION OR RELEASE, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, THE UNITED KINGDOM, AUSTRALIA, CANADA, HONG KONG OR JAPAN, OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN.Oslo, 8 July 2024: Reference is made to the stock exchange announcements published by Circio Holding ASA (the "Company") on 19 June 2024 regarding the general meeting's approval of the rights issue of between 3,658,000 new shares to 20,732,010 new

Circio Holding ASA - Exercise of subscription rights in the rights issue by primary insiders

Oslo, 5 July 2024: Reference is made to the stock exchange announcements by Circio Holding ASA (the "Company") on 24 June 2024, regarding the commencement of the subscription period for the rights issue (the "Rights Issue") and the receipt of subscription rights in the Rights Issue by certain primary insiders and close associates. Damian Marron, Chairman of the board of directors, has on 5 July 2024 exercised 3,604 subscription rights, thus entitling him to be allocated 3,604 offer shares in the Rights Issue. In addition, Damian Marron has subscribed for 140,000 offer shares without

Circio Holding ASA - Exercise of subscription rights in the rights issue by primary insiders

Oslo, 3 July 2024: Reference is made to the stock exchange announcements by Circio Holding ASA (the "Company") on 24 June 2024, regarding the commencement of the subscription period for the rights issue (the "Rights Issue") and the receipt of subscription rights in the Rights Issue by certain primary insiders and close associates. Diane Mellett, a member of the board of directors, has on 3 July 2024 exercised 7,973 subscription rights, thus entitling her to be allocated 7,973 offer shares in the Rights Issue. In addition, Diane Mellett has subscribed for 100,027 offer shares without

Circio Holding ASA – Last day of trading in subscription rights in the rights issue

NOT FOR DISTRIBUTION OR RELEASE, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, THE UNITED KINGDOM, AUSTRALIA, CANADA, HONG KONG OR JAPAN, OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN.Oslo, 2 July 2024: Reference is made to the stock exchange announcement published by Circio Holding ASA (the "Company") on 19 June 2024 regarding the general meeting's approval of the rights issue of between 3,658,000 new shares to 20,732,010 new

Circio Holding ASA - Exercise of subscription rights in the rights issue by primary insiders

Oslo, 28 June 2024: Reference is made to the stock exchange announcements by Circio Holding ASA (the "Company") on 24 June 2024, regarding the commencement of the subscription period for the rights issue (the "Rights Issue") and the receipt of subscription rights in the Rights Issue by certain primary insiders and close associates. Robert Burns, a member of the board of directors, has on 27 June 2024 exercised 19,376 subscription rights, thus entitling him to be allocated 19,376 offer shares in the Rights Issue. In addition, Robert Burns has subscribed for 30,624 offer shares without

Circio Holding ASA – Link to online subscription in the rights issue

NOT FOR DISTRIBUTION OR RELEASE, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, THE UNITED KINGDOM, AUSTRALIA, CANADA, HONG KONG OR JAPAN, OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN.Oslo, 26 June 2024: Reference is made to the stock exchange announcement by Circio Holding ASA (the "Company") on 24 June 2024, regarding the commencement of the subscription period for the rights issue of between 3,658,000 new shares to 20,732,010

Circio invited to present circVec circular RNA technology at upcoming international RNA therapeutics conferences

Oslo, Norway 26 June 2024 – Circio Holding ASA (OSE: CRNA), a biotechnology company developing next generation circular RNA vector technology for gene therapy, today announces that CEO Dr. Erik Digman Wiklund and CSO Dr. Victor Levitsky have been invited to speak at two upcoming biopharma industry RNA conferences in Frankfurt, Germany, and San Diego, USA.The European mRNA conference 2024  Title: Is circular RNA surpassing mRNA as the RNA format for the future? Time & place: 26 June 2024, 11:00 CEST, Frankfurt, Germany Presenter:

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe